Filtered By:
Source: Clinical Cancer Research
This page shows you your search results in order of date. This is page number 2.
Order by Relevance | Date
Total 104 results found since Jan 2013.
Loss of function of DOCK4 in myelodysplastic syndromes stem cells is restored by inhibitors of DOCK4 signaling networks.
CONCLUSIONS: LYN kinase and phosphatases SHP1 and SHIP1 are perturbed when DOCK4 expression levels are low. Inhibition of SHP1 promotes erythroid differentiation in healthy HSCs and in -7/(del)7q MDS samples with low DOCK4 expression. Inhibitors of LYN, SHP1 and SHIP1 also abrogated increased migratory properties in HSCs expressing reduced levels of DOCK4.
PMID: 31308061 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - July 14, 2019 Category: Cancer & Oncology Authors: Sundaravel S, Kuo WL, Jeong JJ, Choudhary GS, Gordon-Mitchell S, Liu H, Bhagat TD, McGraw KL, Gurbuxani S, List AF, Verma A, Wickrema A Tags: Clin Cancer Res Source Type: research
PAK kinase inhibition has therapeutic activity in novel preclinical models of Adult T-cell Leukemia/Lymphoma.
CONCLUSIONS: PAK2, a gene frequently amplified in ATLL, facilitates CADM1-mediated stromal interaction and promotes survival of ATLL cells. Taken together, PAK inhibition may hold significant promise as a targeted therapy for aggressive ATLLs.
PMID: 30862694 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - March 11, 2019 Category: Cancer & Oncology Authors: Chung EYL, Mai Y, Shah UA, Wei Y, Ishida E, Kataoka K, Ren X, Pradhan K, Bartholdy B, Wei X, Zou Y, Zhang J, Ogawa S, Steidl U, Zang X, Verma A, Janakiram M, Ye BH Tags: Clin Cancer Res Source Type: research
Identification of rigosertib for the treatment of recessive dystrophic epidermolysis bullosa-associated squamous cell carcinoma.
CONCLUSIONS: These data support a "first in RDEB" phase II clinical trial of rigosertib to assess tumor targeting in patients with late stage, metastatic and/ or unresectable SCC.
PMID: 30846478 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - March 6, 2019 Category: Cancer & Oncology Authors: Atanasova VS, Pourreyron C, Farshchian M, Lawler ME, Brown CA, Watt S, Wright S, Warkala M, Guttmann-Gruber C, Pinon-Hofbauer J, Fuentes I, Prisco M, Rashidghamat E, Has C, Salas-Alanis JC, Palisson F, Hovnanian A, McGrath JA, Mellerio J, Bauer JW, South Tags: Clin Cancer Res Source Type: research
L-Carnitine Mediated Tumor Cell Protection and Poor Patient Survival Associated with OCTN2 Overexpression in Glioblastoma Multiforme.
CONCLUSIONS: Our data indicates a potential role of the OCTN2/LC system in GBM progression and resistance to therapy, and suggests OCTN2 as a prognostic marker in patients with primary GBM.
PMID: 30670496 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - January 22, 2019 Category: Cancer & Oncology Authors: Fink MA, Paland H, Herzog S, Grube M, Vogelgesang S, Weitmann K, Bialke A, Hoffmann W, Rauch BH, Schroeder HWS, Bien-Möller S Tags: Clin Cancer Res Source Type: research
Regulation of eIF4F translation initiation complex by the peptidyl prolyl isomerase FKBP7 in taxane-resistant prostate cancer.
CONCLUSIONS: Targeting FKBP7 or the eIF4G-containing eIF4F translation initiation complex could be novel therapeutic strategies to eradicate taxane-resistant prostate cancer cells.
PMID: 30322877 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - October 15, 2018 Category: Cancer & Oncology Authors: Garrido MF, Martin NJ, Bertrand M, Gaudin C, Commo F, El Kalaany N, Al Nakouzi N, Fazli L, Del Nery E, Camonis J, Perez F, Lerondel S, LE Pape A, Gleave ME, Loriot Y, Desaubry L, Vagner S, Fizazi K, Chauchereau A Tags: Clin Cancer Res Source Type: research
Combined blockade of activating ERBB2 mutations and ER results in synthetic lethality of ER+/HER2 mutant breast cancer.
CONCLUSIONS: ERBB2 mutations hyperactivate the HER3/PI3K/AKT/mTOR axis, leading to antiestrogen resistance in ER+ breast cancer. Dual blockade of the HER2 and ER pathways is required for the treatment of ER+/HER2 mutant breast cancers.
PMID: 30314968 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - October 12, 2018 Category: Cancer & Oncology Authors: Croessmann S, Formisano L, Kinch L, Gonzalez-Ericsson PI, Sudhan DR, Nagy RJ, Mathew A, Bernicker EH, Cristofanilli M, He J, Cutler RE, Lalani AS, Miller VA, Lanman RB, Grishin N, Arteaga CL Tags: Clin Cancer Res Source Type: research
Inositol trisphosphate receptor type 3-mediated enhancement of EGFR and MET co-targeting efficacy in non-small cell lung cancer detected by 18F-fluorothymidine.
CONCLUSIONS: Our findings indicate that 18F-FLT PET/CT is able to detect the enhanced efficacy of EGFR and MET inhibitors in oncogene-driven NSCLC and that such enhancement is mediated by IP3R3 through its interaction with K-Ras.
PMID: 29618618 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - April 4, 2018 Category: Cancer & Oncology Authors: Iommelli F, De Rosa V, Terlizzi C, Monti M, Panico M, Fonti R, Del Vecchio S Tags: Clin Cancer Res Source Type: research
SMAD4 gene mutation renders pancreatic cancer resistance to radiotherapy through promotion of autophagy.
CONCLUSIONS: Our results demonstrate that defective SMAD4 is responsible for radioresistance in pancreatic cancer through induction of ROS and increased level of radiation-induced autophagy.
PMID: 29602802 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - March 30, 2018 Category: Cancer & Oncology Authors: Wang F, Xia X, Yang C, Shen J, Mai J, Kim HC, Kirui D, Kang Y, Fleming JB, Koay EJ, Mitra S, Ferrari M, Shen H Tags: Clin Cancer Res Source Type: research
Functional precision medicine identifies novel druggable targets and therapeutic options in head and neck cancer.
CONCLUSIONS: High-throughput phenotyping with siRNA and drug libraries using patient derived tumor cells prioritizes mutated driver genes and identifies novel drug targets not revealed by genomic profiling. Functional profiling is a promising adjunct to DNA sequencing for precision oncology.
PMID: 29599409 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - March 29, 2018 Category: Cancer & Oncology Authors: Xu C, Nikolova O, Basom R, Mitchell RM, Shaw R, Moser R, Park H, Gurley KE, Kao M, Green CL, Schaub FX, Diaz RL, Swan HA, Jang IS, Guinney J, Gadi VK, Margolin AA, Grandori C, Kemp CJ, Méndez E Tags: Clin Cancer Res Source Type: research
Capecitabine efficacy is correlated with TYMP and RB expression in PDX established from triple-negative breast cancers.
CONCLUSIONS: we identified capecitabine as efficient chemotherapy in TNBC PDX models established from residual disease and resistant to anthracyclines, taxanes and platins. RB positivity and high expression of TYMP were significantly associated with capecitabine response.
PMID: 29463559 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - February 20, 2018 Category: Cancer & Oncology Authors: Marangoni E, Laurent C, Coussy F, El Botty R, Chateau-Joubert S, Servely JL, de Plater L, Assayag F, Dahmani A, Montaudon E, Némati F, Fleury J, Vacher S, Gentien D, Rapinat A, Foidart P, Sounni NE, Noël A, Salomon A, Lae M, Decaudin D, Roman-Roman S, B Tags: Clin Cancer Res Source Type: research
Ponatinib shows potent antitumor activity in small cell carcinoma of the ovary hypercalcemic type (SCCOHT) through multi-kinase inhibition.
CONCLUSION: Ponatinib is an effective agent for SMARCA4-mutant SCCOHT in both in vitro and in vivo preclinical models through its inhibition of multiple kinases. Clinical investigation of this FDA-approved oncology drug in SCCOHT is warranted.
PMID: 29440177 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - February 9, 2018 Category: Cancer & Oncology Authors: Lang JD, Hendricks WPD, Orlando KA, Yin H, Kiefer J, Ramos P, Sharma R, Pirrotte P, Raupach EA, Sereduk C, Tang N, Liang WS, Washington M, Facista SJ, Zismann VL, Cousins EM, Major MB, Wang Y, Karnezis AN, Sekulic A, Hass R, Vanderhyden BC, Nair P, Weissm Tags: Clin Cancer Res Source Type: research
t-Darpp activates IGF-1R signaling to regulate glucose metabolism in trastuzumab-resistant breast cancer cells.
CONCLUSIONS: t-Darpp activates IGF-1R signaling through heterodimerization with EGFR and HER2 to stimulate glycolysis and confer trastuzumab resistance.
PMID: 29180608 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - November 27, 2017 Category: Cancer & Oncology Authors: Lenz G, Hamilton A, Geng S, Hong T, Kalkum M, Momand J, Kane SE, Huss J Tags: Clin Cancer Res Source Type: research
CD31 Expression Determines Redox Status and Chemoresistance in Human Angiosarcomas.
CONCLUSIONS: Human AS contain a small aggressive CD31(low) population that have lost part of their endothelial differentiation programs and are more resistant against oxidative stress and DNA damage due to intensified YAP signaling. Our finding that the addition of YAP inhibitors can re-sensitize CD31(low) cells towards doxorubicin may aid in the rational development of novel combination therapies to treat AS.
PMID: 29084920 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - October 30, 2017 Category: Cancer & Oncology Authors: Venkataramani V, Küffer S, Cheung KCP, Jiang X, Trümper LHP, Wulf GG, Ströbel P Tags: Clin Cancer Res Source Type: research
Comprehensive pharmacogenomic profiling of malignant pleural mesothelioma identifies a subgroup sensitive to FGFR inhibition.
CONCLUSION: A subgroup of mesotheliomas cell lines harbour sensitivity to FGFR inhibition. BAP1 protein loss enriches for this subgroup, and could serve as a potential biomarker to select patients for FGFR inhibitor treatment. These data identify a clinically relevant MPM subgroup for consideration of FGFR therapeutics in future clinical studies.
PMID: 29061644 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - October 23, 2017 Category: Cancer & Oncology Authors: Quispel-Janssen JM, Badhai J, Schunselaar L, Price S, Brammeld JS, Iorio F, Kolluri KK, Garnett MJ, Berns A, Baas P, McDermott U, Neefjes J, Alifrangis C Tags: Clin Cancer Res Source Type: research
Multilayered omics-based analysis of a head and neck cancer model of cisplatin resistance reveals intratumoral heterogeneity and treatment-induced clonal selection.
CONCLUSIONS: Our study demonstrates a link of intratumoral heterogeneity and clonal evolution as important mechanisms of drug resistance in SCCHN and establishes mutant GOF TP53 variants and the PI3K/mTOR pathway as molecular targets for treatment optimization.
PMID: 29061642 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - October 23, 2017 Category: Cancer & Oncology Authors: Niehr F, Eder T, Pilz T, Konschak R, Treue D, Klauschen F, Bockmayr M, Türkmen S, Jöhrens K, Budach V, Tinhofer I Tags: Clin Cancer Res Source Type: research
